MamtaK(Khandelwal)JainMD

Infectious Disease • Dallas, TX

HIV/AIDS Medicine

Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Dr. Jain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jain's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-2800

Fax+1 214-645-2808

Education & Training

University of Texas Southwestern Medical CenterFellowship, Infectious Disease, 1999 - 2002
Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
Baylor College of MedicineClass of 1996

Certifications & Licensure

TX State Medical License 1997 - 2026
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Board of Directors HIV MA

Clinical Trials

Prospective Observational Epidemiologic Study of Maraviroc's Safety Start of enrollment: 2008 Mar 31
Completed
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Start of enrollment: 2012 Jun 01
Terminated
Phase 4
HBV-HIV Coinfection Research Network Start of enrollment: 2014 Apr 01
Completed
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants Start of enrollment: 2015 Mar 01
Completed
Phase 3
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza Start of enrollment: 2015 Jan 01
Completed
Phase 3
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Start of enrollment: 2015 Mar 26
COMPLETED
PHASE3
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients Start of enrollment: 2015 Feb 23
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) Start of enrollment: 2015 Jun 09
COMPLETED
PHASE3
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Start of enrollment: 2015 Nov 01
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2015 Nov 13
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2015 Nov 11
Completed
Phase 3
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S. Start of enrollment: 2015 Dec 01
Completed
Not Applicable
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment Start of enrollment: 2016 Apr 01
Completed
Phase 3
Atovaquone for Treatment of COVID-19 Start of enrollment: 2020 Jul 22
Completed
Phase 2
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients Start of enrollment: 2005 Sep 01
Completed
Outpatient Treatment With Anti-Coronavirus Immunoglobulin Start of enrollment: 2021 Aug 06
RECRUITING
PHASE3
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Start of enrollment: 2016 Feb 25
Terminated
Phase 4
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Start of enrollment: 2020 Mar 06
Completed
Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Start of enrollment: 2020 Mar 15
Completed
Phase 3
Vaccination for Recovered Inpatients With COVID-19 (VATICO) Start of enrollment: 2021 Aug 25
Completed
Phase 4
ACTIV-2: A Study for Outpatients With COVID-19 Start of enrollment: 2020 Aug 19
COMPLETED
PHASE2, PHASE3
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 Start of enrollment: 2020 Mar 18
Completed
Phase 2, Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19 Start of enrollment: 2020 Aug 04
Completed
Phase 3
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Start of enrollment: 2020 Oct 08
Completed
Phase 3
Adaptive COVID-19 Treatment Trial 4 (ACTT-4) Start of enrollment: 2020 Dec 02
Completed
Phase 3
Adaptive COVID-19 Treatment Trial 3 (ACTT-3) Start of enrollment: 2020 Aug 05
Completed
Phase 3
Adaptive COVID-19 Treatment Trial 2 (ACTT-2) Start of enrollment: 2020 May 08
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Start of enrollment: 2018 Jan 21
TERMINATED
PHASE3
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Start of enrollment: 2018 Jan 03
TERMINATED
PHASE3
Join now to see all

Publications & Presentations

PubMed

Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019.
Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, Barnaby Young, Jacqueline Nordwall
The Journal of Infectious Diseases. 2025-03-17
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial.
Ahmad Mourad, Gregory A Grandits, Lianne K Siegel, Nicole Engen, Christina Barkauskas
Clinical Microbiology and Infection. 2025-02-06
1 citations
Hepatitis Delta Virus Testing and Prevalence Among Chronic Hepatitis B Patients Across Three U.S. Safety-net Health Systems.
Robert J Wong, Mamta K Jain, Bolin Niu, Yi Zhang, George Therapondos
Clinical Gastroenterology and Hepatology. 2024-10-24

Journal Articles

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-Infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study
Mandana Khalili, Mark Sulkowski, Marc G Ghany, Richard K Sterling, Raymond T Chung, David E Kleiner, Mamta K Jain, Nature
Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
Mamta K Jain, Mitchell L Shiffman, Hepatology